Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

N4 Pharma shares jump on latest Nuvec developments

(Sharecast News) - N4 Pharma announced a significant advancement in the development of Nuvec, an innovative delivery system tailored for cancer treatments, gene therapy, and vaccines, on Thursday. The AIM-traded firm reported promising results from in vitro experiments involving the combination of epidermal growth factor receptor (EGFR) and polo-like kinase 1 (PLK1) siRNA molecules onto Nuvec nanoparticles, specifically tested in PC9 lung cancer cells.

It said the findings showed a notable enhancement in cellular inhibition at the 48-hour mark compared to single-dose siRNA treatments, with the synergistic effect of EGFR and PLK1 combination proving particularly impactful.

Notably, when cells were treated with a single dose of 75 nanomolars (nm) of EGFR siRNA, cell viability dropped to 38%, while the same dose of PLK1 siRNA resulted in a viability of 33%.

However, when EGFR and PLK1 were combined at the same dosage, cell viability fell to 19%.

Moreover, the research indicated that the cellular inhibition effect intensified over time, peaking at 48 hours, and correlated with the quantity of siRNA administered.

Consistency in the observed effects was maintained across multiple repetitions of the experiments.

Building on the promising outcomes, N4 Pharma said it planned to further expand its research scope.

That included investigating the knockdown of EGFR alongside bromodomain-containing-protein 4 (BRD4) and extending the analysis of EGFR/PLK1 combination data to a different cell line.

"The work we are doing on multiple loading of siRNA onto one nanoparticle is extremely encouraging and is showcasing the versatility of our Nuvec delivery system," said chief executive officer Nigel Theobald.

"This ability to be able to knockdown two independent pathways leading to a positive added impact is an innovative approach in developing novel cancer treatments aimed at reducing the ability for tumour escape.

"We will continue to present this data to potential licensing partners as all this work strengthens the potential for collaboration opportunities."

At 1021 GMT, shares in N4 Pharma were up 11.2% at 0.83p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

UK consumer confidence hits best level in two years - Deloitte
(Sharecast News) - UK consumer confidence hit its highest level in two years in the first quarter of 2024 as inflation eased, according to a survey released by Deloitte on Friday.
Vector Capital reports robust year-end financial position
(Sharecast News) - Commercial lender Vector Capital reported continued growth in shareholders' equity while maintaining dividends and implementing prudent bad debt provision policies in its full-year results on Friday.
Quadrise posts progress with Utah partner Valkor
(Sharecast News) - Quadrise updated the market on its collaboration with Valkor Technologies in Utah on Friday, targeting the supply of low sulphur 'MSAR' and 'bioMSAR' to the marine and power sector.
Clean Power Hydrogen reports solid full-year progress
(Sharecast News) - UK-based green hydrogen technology company Clean Power Hydrogen (CPH2) reported solid progress towards the commercial rollout of its membrane-free electrolyser (MFE) technology in its final results on Friday, driven by a revamped engineering team.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.